Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999.

BACKGROUND Oral acyclovir is commonly used for genital herpes and other herpesvirus infections. Data on potential fetal risk are extremely limited. From 1984 to 1998, the Acyclovir in Pregnancy Registry monitored birth outcomes of women exposed to oral or intravenous acyclovir during pregnancy. This report describes the final results. METHODS The registry was publicized to health care providers most likely to diagnose pregnancy; providers called the registry telephone number, then mailed in a brief questionnaire. Pregnancy outcomes were categorized either as outcomes with birth defects or outcomes without birth defects, subcategorized as live births, spontaneous pregnancy losses (including stillbirths), and induced abortions. Birth defects were defined using a modification of the CDC definition for birth defects surveillance systems. Observed rates were compared to the rate (3.2%) of birth defects expected in the general population. RESULTS Between June 1, 1984 and June 30, 1998, 1695 pregnancies exposed to oral or IV acyclovir were registered; 461 (27%) were lost to follow-up. A total of 1234 pregnancies in 24 countries were followed, with a total of 1246 outcomes. Among 1246 pregnancy outcomes, 756 involved acyclovir exposure in the first trimester, 197 in the second trimester, and 291 in the third trimester. Among live births with first trimester acyclovir exposure, risk of birth defects was 19 of 596 (3.2%; 95% CI, 2.0-5.0%). No unusual defects or pattern of defects were apparent. CONCLUSIONS The observed rates and types of birth defects for pregnancies exposed to acyclovir did not differ significantly from those in the general population. Birth Defects Research (Part A), 2004. Published 2004 Wiley-Liss, Inc.

[1]  L. Corey,et al.  Effects on infants of a first episode of genital herpes during pregnancy. , 1987, The New England journal of medicine.

[2]  J. Zeh,et al.  Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. , 2003 .

[3]  L. Scott,et al.  Cost-Effectiveness of Acyclovir Suppression to Prevent Recurrent Genital Herpes in Term Pregnancy , 1998, American journal of perinatology.

[4]  P. Sánchez,et al.  Acyclovir Suppression to Prevent Cesarean Delivery After First‐Episode Genital Herpes , 1996, Obstetrics and gynecology.

[5]  J. Kline,et al.  Conception to Birth: Epidemiology of Prenatal Development , 1989 .

[6]  E. Andrews,et al.  Acyclovir in Pregnancy Registry. An observational epidemiologic approach. , 1988, The American journal of medicine.

[7]  C. Druschel,et al.  The epidemiology of infantile hypertrophic pyloric stenosis in New York State, 1983 to 1990. , 1995, Archives of pediatrics & adolescent medicine.

[8]  L. Corey,et al.  Pharmacokinetics of acyclovir in the term human pregnancy and neonate. , 1991, American journal of obstetrics and gynecology.

[9]  M. Honein,et al.  Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study , 1999, The Lancet.

[10]  Z. Brown,et al.  Acyclovir therapy during pregnancy. , 1989, Obstetrics and gynecology.

[11]  M. Guinan,et al.  National Surveillance for Neonatal Herpes Simplex Virus Infections , 1989 .

[12]  L. Melton,et al.  Trends in infantile hypertrophic pyloric stenosis in Olmsted County, Minnesota, 1950-1984. , 1988, Paediatric and perinatal epidemiology.

[13]  G. Burstein,et al.  Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.

[14]  E. Andrews,et al.  Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. , 2000, American journal of obstetrics and gynecology.

[15]  L. Corey,et al.  The management of pregnancies complicated by genital infections with herpes simplex virus. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  L. Paulozzi,et al.  Evaluation of selected characteristics of pregnancy drug registries. , 1999, Teratology.

[17]  R L Ashley,et al.  The acquisition of herpes simplex virus during pregnancy. , 1997, The New England journal of medicine.

[18]  A. Randolph,et al.  Cesarean delivery for women presenting with genital herpes lesions. Efficacy, risks, and costs. , 1993, JAMA.

[19]  R. Kapp,et al.  Preclinical Toxicology Studies with Acyclovir: Teratologic, Reproductive and Neonatal Tests , 1983 .

[20]  P. Sánchez,et al.  Acyclovir suppression to prevent recurrent genital herpes at delivery. , 2002, Infectious diseases in obstetrics and gynecology.

[21]  B. Yankaskas,et al.  Acyclovir in pregnancy registry: six years' experience. The Acyclovir in Pregnancy Registry Advisory Committee. , 1992, Obstetrics and gynecology.

[22]  A. Hartzema,et al.  Acyclovir Use and its Surveillance in a General Population , 1990, DICP : the annals of pharmacotherapy.

[23]  J. Fleiss Statistical methods for rates and proportions , 1974 .

[24]  K. Workowski,et al.  1998 guidelines for treatment of sexually transmitted diseases , 1998 .

[25]  Y. Maldonado,et al.  The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. , 1999, The Journal of infectious diseases.

[26]  S. Soong,et al.  Changing presentation of herpes simplex virus infection in neonates. , 1988, The Journal of infectious diseases.

[27]  I. Chahoud,et al.  Prenatal toxicity of acyclovir in rats , 2004, Archives of Toxicology.